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Background: Targeted PCR-based genetic testing for BRCA1 and BRCA2 can be performed at a lower cost than full
gene testing; however, it may overlook mutations responsible for familial breast and/or ovarian cancers. In the present
study, we report the utility of next generation sequencing (NGS) to identify new pathogenic variants of BRCA1/2.
Methods: BRCA1 and BRCA2 exons were amplified using the Ion AmpliSeq BRCA1/2 Panel and sequenced on the Ion
Torrent PGM sequencer in 512 women with familial and/or only early onset breast and/or ovarian cancers who were
negative for selected BRCA1/2 mutations.
Results: 146 single nucleotide variants (SNVs) and 32 indels were identified. Of them, 14 SNVs and 17 indels were
considered as pathogenic or likely pathogenic. One and 18 pathogenic mutations had been detected previously in
the Polish and other populations, respectively, and 12 deleterious mutations were previously unknown. Eight mutations
were recurrent; Q563X (BRCA1), N3124I (BRCA2) and c.4516delG (BRCA1) were found in eight, six and four patients,
respectively, and two other mutations (c.9118-2A > G and c.7249delCA in BRCA2) were detected in three patients each.
Altogether, BRCA1/2 pathogenic mutations were identified in 52 out of 512 (10%) patients.
Conclusions: NGS substantially improved the detection rates of a wide spectrum of mutations in Polish patients with
familial breast and/or ovarian cancer. Although targeted screening for specific BRCA1 mutations can be offered to all
Polish breast or ovarian cancer patients, NGS-based testing is justified in patients with breast or ovarian cancer likely
related to BRCA1/2 who test negative for the selected BRCA1/2 pathogenic mutations.Background
Approximately 5–10% of breast cancers and 10% of ovar-
ian cancers have a hereditary component [1], which in
most cases is associated with clinically significant muta-
tions in the BRCA1 and BRCA2 genes. According to the
Breast Cancer Information Core (BIC) [2], more than
1800 and 2000 distinct variants of the BRCA1 and BRCA2
genes have been described, respectively. The incidence
and spectrum of mutations vary among populations, and
the carrier frequency in general populations ranges be-
tween 1/40 and 1/800 [3]. Some populations demonstrate
a wide spectrum of mutations, while others are character-
ized by high prevalence of a small number of founder* Correspondence: mikula.michal@gmail.com; jostrow@warman.com.pl
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unless otherwise stated.mutations [4]. In Ashkenazi Jews, three founder mutations
in BRCA1 and BRCA2 comprise 80% to 95% of mutations,
respectively [5,6]. In Poland, the frequency of BRCA1
mutations is estimated to be between 1/240 and 1/360,
and two founder mutations, namely, 5382insC and T300G
(C61G), account for 70–90% of BRCA1 mutations [3].
None of them is unique to Poland.
Breast cancer is the most common cancer among Polish
women, and is a leading cause of cancer-related morbidity
and mortality [7]. The only factor that significantly de-
creases cancer-related mortality is early diagnosis, and in
special cases, prophylactic surgery. Since cancers detected
at an early stage of development are asymptomatic or
low-symptomatic disorders, early diagnosis of cancer is
usually accidental or the result of screening programs.
Current cancer screening guidelines for the general popu-
lation are based on the age of the individual, and patientsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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positive family history of cancer. Families with two first-
or second-degree relatives with breast and/or ovarian can-
cers, with at least one of the cases diagnosed before the
age of 50 years, are considered to be at moderate risk,
while those with at least three relatives with breast and/or
ovarian cancers are considered to be at high risk [7].
The mutation status may determine the medical man-
agement of patients, including annual screening and
prophylactic surgery, and genetic testing for BRCA1 and
BRCA2 is routinely performed in women with hereditary
breast and ovarian cancer risk. More than 100,000 individ-
uals in the United States undergo BRCA testing annually
[8]. However, since BRCA testing is a costly procedure
(the current charge for full gene sequencing is several
hundred to thousands of dollars), most genetic counseling
programs recommend less expensive targeted screening
for specific BRCA1 and BRCA2 mutations rather than full
gene testing [8].
Next generation sequencing (NGS) offers a powerful,
faster, and cheaper alternative for targeted sequencing
aimed at identifying non-synonymous, splicing, and stop
codon variants exhibiting deleterious consequences in the
coding genes [9]. As a consequence, several NGS-based
workflows for clinical BRCA1 and BRCA2 mutation test-
ing were recently proposed [10-16].
In a previous study from our group, we used multi-
plexed PCR-based genotyping technology and showed that
the frequency of selected BRCA1 mutations was moderate
in familial and high in nonfamilial breast cancers. In
addition, a strong founder effect was confirmed for
BRCA1 mutations but not for BRCA2 mutations in the
Polish population [7]. In the present study, we show that
the use of the Ion Torrent PGM sequencer to sequence
the coding exons of BRCA1 and BRCA2 genes substan-
tially improves the detection rates of a wide spectrum of
mutations in Polish patients with familial and/or only
early onset of breast and/or ovarian cancers.
Methods
Patients
Patients whose blood samples were collected between
2003 and 2010 were selected from the registry of the Gen-
etic Counseling Unit, Warsaw Cancer Center-Institute of
Oncology. The personal and familial cancer histories were
acquired by in-depth interviews. Healthy individuals with
no known personal or familial history of malignancy, nor-
mal results of screening colonoscopy, and normal mam-
mography or PSA levels were recruited primarily from the
National Colorectal Cancer Screening Program. All pa-
tients and control subjects were Polish Caucasians re-
cruited from the Masovian voivodeship population.
Informed consent for hereditary cancer genetic testing
was obtained from all of the patients. The permission forgenetic testing was granted by the Ethical Committee at
Maria Sklodowska-Curie Memorial Cancer Center and In-
stitute of Oncology on 9 May 2002 (No. 28/2002) and fur-
ther extended to include testing with NGS on 11 June
2013 (No. 28/2002/1/2013). The study did not require
ethical approval.
BRCA1/2 sequencing
Genomic DNA was extracted from whole blood as de-
scribed previously [7]. DNA concentration was deter-
mined on a Qubit 2.0 Fluorometer using the Qubit
dsDNA BR Assay Kit (Life Technologies). For library
preparation, a set of reagents from the Ion AmpliSeq™ Li-
brary Kit 2.0 (Life Technologies) and Ion AmpliSeq
BRCA1 and BRCA2 Panel, which comprises 167 primer
pairs spanning 16.25 kb, were used to amplify the coding
regions of the BRCA1 and BRCA2 genes. Amplification
for each patient was performed using three separate pri-
mer pools containing 1.4 μl of 5× Ion AmpliSeq™ HiFi
Master Mix, 3.5 μl of 2× Ion AmpliSeq Primer Pool, and
3 ng of DNA in a total reaction volume of 7 μl. Cycling
conditions were as follows: 99°C for 2 min, followed by
19 cycles of 99°C for 15 sec and 60°C for 4 min, ending
with a hold at 10°C. At this point, three separate reactions
for a given patient were combined, and amplicons were
partially digested at primer sequences with 2 μl of FuPa
reagent under conditions provided by the manufacturer in
The Ion AmpliSeq DNA and RNA Library Preparation
protocol (Revision B.0). Subsequent steps of library prep-
aration were performed according to the above protocol.
Briefly, following digestion, samples were subjected to se-
quencing adapter ligation with either 16 or 32 indexing
barcodes, and purified with the AMPure XP reagent
(Beckman Coulter). The DNA library was eluted from
AMPure XP beads with 52 μl of PCR reagent solution
consisting of 50 μl of Platinum®PCR Super Mix HiFi and
2 μl of Library Amplification Primer Mix, and amplified
under the following conditions: 98°C for 2 min, followed
by five cycles of 98°C for 15 sec and 64°C for 1 min, end-
ing with a hold at 10°C. Next, the amplified DNA library
was subjected to a two-round purification process using
AMPure XP beads with 0.5× and 1.2× bead-to-sample vol-
ume ratios, respectively. Library concentrations were de-
termined with the Qubit dsDNA HS Assay Kit (Life
Technologies), and the respective size distributions were
determined with the High Sensitivity DNA Analysis Kit
on Bioanalyzer 2100 (Agilent).
Library molarity was determined, and either 16 or 32 li-
braries were pooled in equimolar concentrations and used
for automatic template preparation on Ion Chef using re-
agents from the Ion PGM IC 200 Kit and Ion 316 Chip
Kit v2 BC. Sequencing was performed on the Ion Torrent
PGM sequencer using 500-flow runs. Data from the PGM
runs were processed on the Ion Torrent server using a
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v4.2.1 (Life Technologies) to obtain sequence reads, trim
adapter sequences, filter and remove poor signal reads,
and assign the reads to a given barcode. The reads were
mapped to the hg19 (Homo sapiens) reference genome
and adjusted to the specific amplicon target regions de-
posited in the “BRCA1_2.20131001.designed” BED file
available in Torrent Suite. The coverageAnalysis (v4.2.1.4)
and variantCaller (v4.2.1.0) plug-ins with a set of default
parameters optimized for the BRCA1/BRCA2 panel were
obtained from www.Ampliseq.com, and were ran for each
sequencing dataset.
Post-sequencing variant analysis
Variants were classified either as single nucleotide variants
(SNVs) or insertion/deletion (indels) variants using a py-
thon script. Variants were annotated using data from BIC
for the BRCA1 and BRCA2 genes. The identified variants
were matched to existing variants in BIC according to four
parameters as follows: chromosome number (chromo-
some 13 and chromosome 17 for BRCA2 and BRCA1, re-
spectively); position of the variant in the human genome
assembly hg19 (GRCh37), which was retrieved from the
BIC database field HGVS; genomic and type of reference;
and alternate base. The possibility of different alternate
and reference base was taken into account as well as the
possibility of variant on the reverse strand.
All the SNVs were analyzed using Variant Effect Pre-
dictor [17] (VEP) for the human genome assembly hg19
(GRCh37). The occurrence of variants was determined
using an R script. Variants with unknown clinical signifi-
cance in BIC and new changes were subjected to in silico
analysis of their deleteriousness, and screened for evidence
of pathogenicity in the literature.
Selection of pathogenic variants
SNVs and indels were analyzed using Condel [18] and
SIFT Indel [19], respectively. Missense variants were clas-
sified as pathogenic when reported in BIC as pathogenic,
and/or predicted as pathogenic by a Condel score, and
identified through a literature search [20-29]. Frameshift
mutations were classified as pathogenic when reported as
pathogenic by BIC and/or predicted as pathogenic by
SIFT Indel.
Genotyping
Pathogenic mutations detected by NGS were confirmed
by Sanger sequencing. In addition, five selected variants,
namely, Q356R, N3124I, Q563X, c.7249delCA, and
c.9118-2G > A, were genotyped using Custom TaqMan
SNP Genotyping Assays (Life Technologies, USA) and a
7900HT Real-Time PCR system (Life Technologies) as de-
scribed previously [7].Results
NGS analysis
The incidence of SNVs and indels within 167 amplicons
covering the BRCA1 and BRCA2 exons was tested using
the Ion Torrent PGM sequencer in 31 (a training set)
and 512 women with breast cancer or ovarian cancer
newly diagnosed before the age of 50 years who were posi-
tive and negative for BRCA1/2 mutations, respectively,
as determined by targeted genotyping. The genotyping
comprised 11 mutations in BRCA1, namely c.66_67delAG,
C61R, c.3700_3704del5, c.3756delGTCT, c.3777delT,
c.4035delA, c.4041delAG, c.4065delTCAA, c.5263delC,
R1738E and R1751X, and nine mutations in BRCA2,
namely E394X, c.5239insT, c.5946delT, c.5964delAT,
c.6447delTA, c.7910del5, c.8924delT, R3128X and
c.9402delT [7,30]. Of the 512 women, 317 had familial
breast and/or ovarian cancer, and 195 had only early onset
cancer and/or contralateral breast and ovarian cancers;
the median age of women with breast cancer at diagnosis
was 43 years.
The average number of bases with ≥Q17/≥Q20 across
all 21 PGM sequencing runs was 343/324 Mbp, constitut-
ing 96/90% of total output. The average coverage across
all samples was 507, whereas the mean mapping rate
reached 94%.
The NGS-based procedure confirmed the pathogenic
mutations in all 31 DNA samples of a training set (not
shown). Among 512 DNA samples analyzed, we identified
146 SNVs (64 in BRCA1 and 82 in BRCA2) and 32 indels
(20 in BRCA1 and 12 in BRCA2). Sixteen indels were
found in coding regions (nine in BRCA1 and seven in
BRCA2). The results of the detailed analysis of SNVs and
indels are summarized in Additional file 1.
The types and number of SNVs are summarized in
Table 1. Of these, eight SNVs (five in BRCA1 and three in
BRCA2) were already reported in BIC as pathogenic.
Three additional SNVs were reported as variants of uncer-
tain significance (VUS); variants co-localized with these
SNVs were reported as pathogenic in ClinVar. In addition,
we identified three novel nonsense variants (Table 2). Of
41 missense variants that were either reported as VUS in
BIC or had not been reported previously, 24 had at least
one transcript in which the Condel score was reported as
deleterious (Table 3).
Of the indels identified in the present study, five in
BRCA1 and two in BRCA2 had already been reported in
BIC as pathogenic. One additional indel was reported as
unknown in BIC, although its co-located variants in
dbSNP were reported in ClinVar as pathogenic (Table 4).
We also found nine novel indels in coding regions
(Table 4).
Altogether, among 512 patients in whom the previous tar-
geted genotyping did not reveal a pathogenic BRCA1/2 mu-
tation massive amplicon sequencing identified 52 patients
Table 1 Types and number of single nucleotide variants
in the BRCA1 and BRCA2 genes
Type of variant Number
BRCA1 BRCA2
Intronic variant 21 23
Intronic variant near splice site 3 4
Missense variant 25 36
Nonsense variant 6 3
Synonymous variant 4 14
Variant in the splice region of exon 0 1
3′ or 5′ UTR variants 5 1
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frameshift, eight were nonsense, three were missense, and
four affected splicing. Of note, one patient carried two
pathogenic mutations, namely Q563X and N3124I. All
pathogenic variants were confirmed by Sanger direct se-
quencing. Five other variants were likely pathogenic, and
17 variants were VUS. All of them were missense muta-
tions (Table 3).Genotyping for NGS-selected mutations
Using the TaqMan SNP Genotyping Assay, the incidence of
five selected variants, one common polymorphism (Q356R)
and four mutations (N3124I, Q563X, c.7249delCA, and
c.9118-2G >A) were tested in additional group of 445 can-
cer patients diagnosed under the age of 50 and 1300Table 2 Pathogenic single nucleotide variants in BIC and
ClinVar
Variant Type Evidence of pathogenicity Count
BRCA1
Q563X * Nonsense BIC, ClinVar 8
W1782X Nonsense BIC, ClinVar 2
Y1563X Nonsense BIC, ClinVar 1
Q538X Nonsense BIC, ClinVar 1
E1415X Nonsense 1
C1501X Nonsense 1
R1699W Missense BIC, ClinVar 2
BRCA2
Q92X Nonsense BIC, ClinVar 1
c.9118-2A > G IVS BIC, ClinVar 3
P3039P Splice BIC, ClinVar 1
Q3047X Nonsense 1
N3124I Missense ClinVar, Condel 6
I2627F Missense ClinVar, Condel 1
c.8754 + 5G > T IVS ClinVar 2
* Patients with ovarian and breast cancer.
IVS intronic variant near splice site; Splice variant in the splice region of exon.healthy individuals (856 women and 444 men with a me-
dian age of 59 years).
Although Q356R was described as pathogenic in Clin-
Var, its prevalence was similar among patients (15.1%) and
healthy controls (16.9%). Therefore, the clinical signifi-
cance of this polymorphic variant was not confirmed. By
contrast, Q563X was detected in 5 (1.1%) out of 445 can-
cer patients, respectively, but only in one healthy individ-
ual. The three other mutations (N3124I, c.7249delCA, and
c.9118-2G > A) were detected by TaqMan genotyping only
in DNA samples in which they were identified by NGS.
Discussion
The rare germline pathogenic BRCA1 mutations increase
the risk of breast and ovarian cancer to approximately
80% and 60%, respectively, whereas BRCA2 mutations in-
crease breast cancer risk to more than 80% by the age of
80 [10]. Because the risk of cancer can be predicted by a
family history and/or by an early disease onset, the Gen-
etic Counseling Unit at the Warsaw Cancer Center-
Institute of Oncology offers risk counseling based on the
occurrence of cancer in the pedigree. However, according
to Polish guidelines and recommendations, the govern-
ment sponsored surveillance program, which includes an-
nual mammography and breast magnetic resonance
imaging, pelvic ultrasonography, and cancer antigen 125
levels, is provided only to women with known pathogenic
mutations. Therefore, in families with an increased cancer
risk, genetic testing is critical for preventive healthcare, in-
cluding specialized surveillance programs and prophylac-
tic mastectomy and/or oophorectomy, which reduce the
risk of breast/ovarian cancer by over 90% [31]. The detec-
tion of BRCA1/2 pathogenic mutations facilitates the se-
lection of patients and the delivery of healthcare and
related services in women harboring their respective
germline mutations.
Although BRCA1 and BRCA2 mutations [32-37] are
present in more than 60% and 30% of families, respect-
ively, our targeted mutation screening [7] detected 20.8%
and 1.3% of patients carrying pathogenic BRCA1 and
BRCA2 mutations, respectively. This suggests that a pro-
portion of mutations responsible for familial breast and/or
ovarian cancers were not identified. In the present study,
we report the utility of NGS for the detection of new
pathogenic variants of BRCA1/2.
Among 512 DNA samples analyzed, we identified 146
SNVs and 32 indels, of which 14 SNVs and 17 indels were
considered as pathogenic or likely pathogenic. One and 18
pathogenic mutations had been detected previously in the
Polish and other populations, respectively, and 12 deleteri-
ous mutations had not been detected earlier. Eight muta-
tions were recurrent; Q563X, N3124I and c.4516delG were
found in eight, six and four patients, respectively, and two
other mutations (c.9118-2A >G and c.7249delCA) were
Table 3 Pathogenic missense variants according to the Condel algorithm
Variant Gene rs Count Condel count Condel max Condel algorithms Confirmed by other models
Q356R BRCA1 rs1799950 72 12 0.70898 4 no
S1040N BRCA1 rs4986852 11 7 0.66416 3 no
K1690N BRCA2 rs56087561 10 2 0.536316 2 no
N3124I BRCA2 rs28897759 6 2 0.618793 4 yes
R1347G BRCA1 rs28897689 6 7 0.540272 2 no
Q2858H BRCA2 - 3 2 0.539229 3 novel
V2969M BRCA2 rs59004709 2 2 0.644176 3 no
D1152N BRCA1 rs80357175 2 7 0.596261 2 no
T1011R BRCA2 rs80358548 1 2 0.531615 2 no
E2236K BRCA2 rs41293503 1 2 0.591769 2 no
S2326C BRCA2 - 1 2 0.599866 2 novel
I2627F BRCA2 rs80359014 1 2 0.663608 4 yes
L2865F BRCA2 - 1 2 0.593408 3 novel
V1791L BRCA1 rs145758886 1 11 0.574356 3 no
Y1703C BRCA1 - 1 14 0.622922 4 novel
A1669S BRCA1 rs80357087 1 13 0.540083 3 no
M1628T BRCA1 rs4986854 1 13 0.526967 1 no
E1346K BRCA1 rs80357407 1 7 0.540139 1 no
R866H BRCA1 rs80356911 1 7 0.676062 4 no
N723D BRCA1 rs4986845 1 7 0.543268 1 no
N550H BRCA1 rs56012641 1 9 0.681765 4 no
F486L BRCA1 rs55906931 1 9 0.558913 1 no
Y179C BRCA1 rs56187033 1 20 0.588385 4 no
G602R BRCA1 - 1 14 0.660547 4 novel
Condel count: number of transcripts in which a given variant is deleterious; Condel max: maximal score from Condel; Condel algorithms: maximum number of
algorithms (used in Condel score computation) in which a given variant is marked as deleterious.
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cing of BRCA1/2 coding exons identified additional pre-
dicted cancer risk mutations in 52 out of 512 (10%)
patients with familial and/or an early onset breast/ovarian
cancer that were missed using our standard genotyping
procedure. The incidence of new pathogenic mutations was
higher in women with familial breast and/or ovarian cancer
[26 mutations (17.9%) in 145 patients] than those repre-
senting only familial breast cancer [26 (7.1%) in 367 pa-
tients]. These mutations could be used for estimation of
cancer risk in index patients and for cascade screening.
The pathogenicity of nonsense and frameshift mutations
was relatively easily established; however, the functional
consequences of several missense, intronic, and small in-
frame insertion/deletions were not as evident, and reaching
an adequate conclusion and providing advice regarding
their significance were challenging tasks. These unclassi-
fied VUSs are not communicated to the patient or to
non-genetic professionals to avoid increasing healthcare
utilization and costs associated with unnecessary physician
visits and imaging tests [38-41]. Therefore, it is urgent todevelop functional studies to evaluate the pathogenicity of
a suspected variant and determine its involvement in
breast and/or ovarian cancer development. New genome
editing techniques enable the assessment of genetic vari-
ants, including those of uncertain significance, in a native
chromosomal context [42]. For example, in a proof of con-
cept study, known mutations and artificial variants in
exon18 BRCA1 were introduced using the CRISPR/Cas9
technique, resulting in traceable changes in BRCA1 mRNA
splicing and abundance [43]. Such an approach, when
scaled up, allows the evaluation of the combination effects
of variants on splicing and transcript levels in any gene.
The overall mutation prevalence in the combined results
of previous targeted genotyping studies [7] and the present
amplicon sequencing was >30% in a group of patients with
early onset breast/ovarian cancer. However, the negative
results of genetic testing may not be universally informative
for assessing cancer risk and do not rule out hereditary
predisposition. The lack of detection of pathogenic muta-
tions in families affected by an increased risk of breast/
ovarian cancer may result not only from misinterpretation
Table 4 Pathogenic indels in BIC, ClinVar, or SIFT indel prediction
Variant rs Type BIC ClinVar SIFT Count
BRCA1
c.4516delG rs273900736 F pathogenic not-tested 4
c.5137delG rs80357997 F pathogenic pathogenic not-tested 1
c.1695insG rs273897664 F pathogenic not-tested 1
c.340delTC rs80357881 F pathogenic not-tested 1
c.5285insG rs80357886 F pathogenic not-tested 1
c.4597delGA F pathogenic 1
c.5232del7ins12 F pathogenic 1
c.403delA F pathogenic 1
c.403delAAGA F pathogenic 1
BRCA2
c.7249delCA F pathogenic 3
c.475 + 4delT rs276174848 IVS unknown likely pathogenic not-tested 1
c.696delT rs80359630 F pathogenic not-tested 1
c.2808delACAA rs80359352 F pathogenic not-tested 1
c.1318delCTTA F pathogenic 1
c.8840delA F pathogenic 1
c.8942delA F pathogenic 1
c.9375delC F pathogenic 1
IVS intronic variant near splice site, F frameshift variant.
Figure 1 Mutations found in BRCA1 and BRCA2 genes. Visualization was performed with MutationMapper [55]. The Pfam protein domains and
the positions of specific mutations are shown. The mutations found in two or more cases are labeled.
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Table 5 Example of multilevel genetic testing workflow
that led to identification of BRCA1 C1501X mutation in
multiple family members during conducting this study



























seven out of eight
studied relatives #
*Eleven BRCA1 mutations (c.66_67delAG, C61R, c.3700_3704del5, c.3756delGTCT,
c.3777delT, c.4035delA, c.4041delAG, c.4065delTCAA, c.5263delC, R1738E and
R1751X) and nine BRCA2 mutations (E394X, c.5239insT, c.5946delT, c.5964delAT,
c.6447delTA, c.7910del5, c.8924delT, R3128X and c.9402delT) [7,30].
#family tree is depicted in Additional file 2.
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tion of index women and/or the genetic analytical range
[1]. Additionally, for some populations the large rearrange-
ments in BRCA1/2 genes have been described in a signifi-
cant proportion of families with strong breast/ovarian
cancer history [45,46]. However, in Poland such testing is
not routinely performed since no founder mutations were
described [47]. In addition, amplicon sequencing with
PGM platform does not seem to be a method ready for
searching of BRCA1/2 large rearrangements in genetic
counseling [11,48].
The presence of germline mutations in cancer suscepti-
bility genes other than BRCA1/2 may also lead to the de-
velopment of hereditary breast/ovarian cancers. An NGS
25-gene panel revealed that the frequency of mutations in
genes other than BRCA1/2 is 4.3%, of which 3.9% are in
genes associated with breast/ovarian cancer [49]. The 4.3%
frequency of germline mutations in additional cancer sus-
ceptibility genes was also detected through analyses of
breast cancers in The Cancer Genome Atlas Project [50].
However, with the exception of PALB2, most of these pre-
disposition genes do not reach the same degree of signifi-
cance as BRCA1 predisposition [51], and in contrast to
BRCA1/2 mutations, neither age at breast cancer diagnosis
nor family history of ovarian or young breast cancer are
predictive factors for other mutations [49].
Conclusions
NGS testing might be routine for many genes, including
BRCA1 and BRCA2. However, the cost of complete genetic
testing is significantly higher than that of conventional
PCR-based genetic testing; the internal costs in our institu-
tion, excluding personnel and overhead, are $120 vs. $20
[7]. Therefore, introducing the NGS to routine genotypingof BRCA (and other genes) in clinical practice would need
additional financial support from public healthcare sys-
tems. Instead, targeted screening for specific BRCA1 muta-
tions performed at the reasonable costs can be offered to
all breast or ovarian cancer patients in the Polish popula-
tion, regardless of the family history or the age of disease
onset [7,52-54]. Since PCR-based cost-efficient testing for
BRCA1 and BRCA2 can detect mainly pre-selected muta-
tions, the more recurrent mutations included in the
screening, the greater efficiency of the testing.
In the present study, we identified two mutations,
namely, Q563X (BRCA1) and N3124I (BRCA2), showing a
strong founder effect in the Polish patients with a heredi-
tary risk of ovarian/breast cancer. These mutations should
be included in the set of mutations analyzed in PCR-based
targeted screening programs in Poland. Sanger direct se-
quencing should be used to confirm the presence of a
pathogenic mutation detected by PCR- or NGS-based
genotyping, and it is the method of choice for cascade
screening of relatives of the index patient. Finally, NGS-
based testing of all coding exons in both genes may be re-
served for patients with breast or ovarian cancer that is
more likely related to BRCA. These considerations for the
comprehensive assessment of pathogenic mutations in
breast and ovarian cancers are exemplified for BRCA1
C1501X mutation found in multiple family members dur-
ing conducting this study (Table 5 and Additional file 2).
However, further studies are required to determine which
clinical features may better define a feasible link between
breast/ovarian cancer and BRCA1/2 mutations.
Additional files
Additional file 1: Contains Table S1 and Table S2 with a list of single
nucleotide variants and indels, respectively, found in BRCA1/2 genes.
Additional file 2: Family tree harboring C1501X mutation in BRCA1.
BRC; breast cancer, RRM; risk reduction mastectomy, RRA; risk reduction
adnexectomy; DLBCL; diffuse large B-cell lymphoma.
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